Executive Summary

Chimeric antigen receptor T cell therapy has established a distinct category of genetically modified cellular immunotherapies. Since the first FDA approval in 2017, seven products have entered the United States market for selected leukemias, lymphomas, and multiple myeloma. Their development demonstrates the clinical utility of directing T cells against antigens expressed by malignant B cells and plasma cells.

The approved products share a common therapeutic principle but differ in receptor design, signaling domains, cellular composition, manufacturing, dosing, and indications. These distinctions have become increasingly relevant as sponsors seek better persistence, improved safety, shorter treatment timelines, and access to patients earlier in their disease course.

Development now extends beyond established blood cancer indications. Investigational products target additional antigens, combine recognition of multiple targets, employ genome editing to generate donor derived cells, and introduce resistance to suppressive signals within solid tumors. Clinical programs involving autoimmune diseases are also testing whether targeted elimination of pathogenic immune cell populations can produce durable treatment responses.

Regulatory progress has accompanied technological development. FDA removed the Risk Evaluation and Mitigation Strategies requirements for six established CAR T products in June 2025, while maintaining product labeling warnings and long term safety surveillance. New indications, manufacturing modifications, and emerging treatment platforms continue to require substantial evidence of effectiveness, product consistency, and appropriate characterization of risk.

International developments provide another perspective. China approved a CAR T therapy for a solid tumor in 2026, while India has established domestic CAR T development and manufacturing capabilities. Across Europe, reimbursement disparities and treatment center capacity continue to constrain access. These developments place manufacturing efficiency, clinical differentiation, and market implementation alongside biological efficacy as central considerations for the next generation of CAR T therapies.

CAR Technology: Receptor Design and Target Recognition

Chimeric antigen receptor (CAR) T cell therapy uses genetically modified T lymphocytes to recognize selected antigens on target cells. A typical CAR contains an extracellular antigen binding domain, a hinge and transmembrane region, and intracellular signaling components. Most licensed products incorporate a CD3 zeta activation domain together with a costimulatory domain derived from CD28 or 4-1BB, also known as CD137. Antigen engagement activates the modified T cell and can initiate proliferation, cytokine secretion, and killing of target cells. 12

Unlike conventional T cell receptors, CARs can recognize suitable cell surface antigens without requiring antigen presentation through the major histocompatibility complex (MHC). The choice of target antigen determines the population of cells susceptible to elimination, including healthy cells expressing the same antigen. Consequently, target selection influences both the therapeutic mechanism and anticipated toxicities. 12

The initial commercial products predominantly employ second generation CAR architectures. The CD28 and 4-1BB signaling domains provide different costimulatory inputs, while antigen binding affinity, receptor density, cell composition, and manufacturing conditions introduce additional variability. The relationship between an individual design feature and clinical outcomes must be established within the relevant product and patient population. 234

FDA Approved CAR T Products

As of October 31, 2026, seven distinct CAR T cell products have received FDA approval. Five target CD19 in B cell malignancies, and two target BCMA in multiple myeloma. All seven are autologous products manufactured using cells collected from the individual patient. The approved indications have expanded through supplemental applications, with several therapies now available in earlier treatment settings or additional lymphoma subtypes. 56789101112

The seven products represent seven separate biologic licenses rather than a uniform therapeutic class with interchangeable indications. Patient eligibility depends on the precise FDA approved indication, including disease subtype, age, previous treatments, and other applicable limitations. Some indications remain subject to accelerated approval requirements. 6791011

CAR T Cell Therapy: FDA Approvals and Emerging Technologies (2017–2026)

Click to enlarge

What Differentiates the Approved Technologies?

Kymriah established the clinical use of a CD19 directed CAR containing a 4-1BB costimulatory domain and CD3 zeta signaling domain. Yescarta employs CD28 costimulation with CD3 zeta signaling. These intracellular architectures provide different activation signals, although differences in patient populations, disease characteristics, and trial designs limit conclusions from comparisons between products. 671314

Tecartus shares the CD19 targeting and CD28 signaling approach used by Yescarta but incorporates a T cell enrichment step during manufacturing. Its prescribing information describes the potential for this step to reduce the influence of circulating CD19 expressing tumor cells in the starting material. This illustrates how manufacturing design can become a distinguishing feature even when the principal antigen target and intracellular signaling domains are similar. 1513

Breyanzi employs separate CD4 positive and CD8 positive T cell components administered in a defined 1:1 ratio, together with 4-1BB costimulation. Its broad indication portfolio illustrates how a cellular product may undergo successive clinical development programs in biologically related malignancies while maintaining a common core receptor architecture. FDA approved an indication for marginal zone lymphoma in December 2025, and the agency's current product information includes additional lymphoma and leukemia indications. 916

The two approved BCMA products illustrate a difference in antigen recognition. Abecma uses an anti BCMA single chain variable fragment coupled to 4-1BB and CD3 zeta signaling domains. Carvykti uses two linked single domain antibody regions recognizing BCMA, together with the same broad classes of intracellular signaling components. These structural differences are relevant to antigen binding and receptor characterization, but product superiority cannot be inferred from receptor design alone. 174

Aucatzyl introduced another design approach based on receptor binding kinetics. Its CAT19 binding domain has lower affinity and faster dissociation from CD19 than the commonly used FMC63 binder. The design seeks to moderate sustained receptor engagement and associated T cell activation. The FELIX development program also employed tumor burden guided administration of divided doses. These features illustrate the potential importance of binding kinetics and administration strategy in managing immunotoxicity. 31812

The Evolution of FDA Regulatory Oversight

The regulatory history of CAR T therapy illustrates the transition from initial licensing of a new therapeutic modality to continued expansion of established products. FDA granted the first CAR T approval in August 2017. Subsequent development included additional cancer indications, changes in treatment line, and supplemental applications supported by distinct clinical datasets. The expansion of Carvykti into an earlier multiple myeloma treatment setting in April 2024 and Breyanzi into marginal zone lymphoma in December 2025 exemplifies this progression. 61116

Several CAR T indications have been approved through the accelerated approval pathway, including specified follicular lymphoma indications and the chronic lymphocytic leukemia or small lymphocytic lymphoma indication for Breyanzi. These approvals rely on evidence considered reasonably likely to predict clinical benefit and retain obligations for verification and description of clinical benefit. The approval pathway therefore remains a product and indication specific element of the development strategy. 679

On June 26, 2025, FDA eliminated the Risk Evaluation and Mitigation Strategies (REMS) requirements for six approved autologous CAR T therapies directed against CD19 or BCMA. FDA concluded that established clinical experience and available management practices permitted safe use without the REMS framework. The decision removed designated facility certification requirements associated with those REMS programs and was accompanied by changes to patient monitoring and proximity instructions. Aucatzyl, approved in November 2024, had entered the market without a REMS requirement. 1920

Removal of REMS requirements did not remove the principal treatment risks. FDA continues to require warnings and safety monitoring for cytokine release syndrome (CRS), neurological toxicities, and secondary malignancies. In April 2024, FDA required boxed warnings addressing T cell malignancies following treatment with products directed against CD19 or BCMA. FDA's June 2025 REMS decision also retained requirements for long term postmarketing observational safety studies involving patient follow up for 15 years. 1921

Product specific safety findings remain relevant. On October 10, 2025, FDA announced a boxed warning update for Carvykti concerning immune effector cell associated enterocolitis, based on clinical trial and postmarketing reports. This safety issue underscores the continuing importance of pharmacovigilance after initial licensing and of evaluating delayed adverse reactions associated with individual CAR T products. 22

The Hematologic Oncology Development Pipeline

The investigational CAR T pipeline includes modifications to established targets and approaches intended to address limitations of available treatments. Current strategies include alternative antigen binding domains, simultaneous recognition of multiple antigens, use of healthy donor T cells, and administration earlier in the treatment sequence. Programs are progressing through different stages of clinical development, and the evidence available for each remains specific to the investigated population and study design. 23242526

Anitocabtagene autoleucel, or anito-cel, is an investigational BCMA directed autologous CAR T product developed using a compact D Domain antigen binding architecture. The biologics license application for treatment of adults with relapsed or refractory multiple myeloma after at least three prior lines of therapy was accepted by FDA, with an announced target action date of December 23, 2026. The application is supported by Phase 1 and pivotal Phase 2 iMMagine-1 clinical studies. At the October 2026 cutoff, anito-cel remains investigational. 23

Dual antigen recognition is another development direction. Gilead's KITE-753 program combines CD19 and CD20 recognition in an investigational bicistronic CAR T approach. Its development program includes a Phase 3 study in diffuse large B cell lymphoma. The underlying rationale is to broaden target recognition and address a potential mechanism of relapse involving variation in tumor antigen expression, although the clinical benefit of the approach remains under investigation. 24

Allogeneic CAR T: Manufacturing at Scale

Autologous CAR T manufacturing begins with collection of an individual patient's cells, followed by genetic modification, expansion, testing, and return of the manufactured product for infusion. The process introduces patient specific manufacturing variability and requires coordination among collection sites, manufacturers, and treatment centers. Allogeneic CAR T approaches seek to produce therapeutic cells from healthy donors, potentially enabling larger manufacturing batches and inventory available before an individual patient requires treatment. 127

Engineering donor derived T cells introduces additional biological challenges. Endogenous T cell receptors can contribute to graft versus host disease, while recognition of donor cells by the recipient immune system can limit cellular persistence. Investigational approaches therefore employ modifications to T cell receptor genes, antigen presentation pathways, or inhibitory signaling mechanisms. The resulting products require characterization of editing efficiency, unintended genetic modifications, cellular phenotype, and functional activity. 126

Cema-cel exemplifies development around a defined treatment window. Allogene's ALPHA3 study evaluates donor derived CD19 directed CAR T treatment in patients with large B cell lymphoma who remain positive for measurable residual disease after initial treatment. In August 2026, Allogene reported that an interim analysis supported continuation of the study and that FDA had granted Regenerative Medicine Advanced Therapy and Fast Track designations. These developments concern an investigational product and do not establish clinical benefit sufficient for approval. 25

ALLO-329 represents a distinct use of dual antigen targeting. The product recognizes CD19 and CD70, with CD70 targeting intended to interfere with activated host immune cells that could contribute to rejection of donor derived CAR T cells. The ongoing RESOLUTION study is evaluating the technology in autoimmune disease, including different lymphodepletion approaches. Its development addresses one of the central barriers to donor derived cellular therapy: achieving adequate expansion and persistence in the recipient. 25

Commercial development risks are substantial even when clinical programs progress. On October 6, 2026, Caribou Biosciences announced plans to discontinue development of its two investigational allogeneic CAR T programs, vispacabtagene regedleucel and CB-011, while evaluating strategic alternatives. The company cited difficulty securing financing to advance these programs. The announcement illustrates the capital requirements associated with late stage cell therapy development and the possibility that financing constraints can interrupt a program despite prior FDA engagement. 28

CAR T Cell Therapy in Autoimmune Diseases

Autoimmune disease has become an important investigational application of CAR T therapy. In this setting, CD19 directed approaches seek to eliminate B cell populations contributing to pathological immune responses. The therapeutic hypothesis is that substantial B cell depletion followed by immune reconstitution may produce sustained improvement in selected diseases. This strategy introduces questions concerning the duration of benefit, effects on protective immunity, patient selection, and the suitability of an intensive cellular treatment for chronic conditions. 293026

Reescabtagene autoleucel, or rese-cel, is an investigational autologous CD19 CAR T therapy being developed by Cabaletta Bio. Its RESET program includes myositis, systemic lupus erythematosus, systemic sclerosis, and other autoimmune conditions. In its August 2026 update, Cabaletta described plans for a registrational myositis program and a subsequent biologics license application, together with development of a registrational cohort in systemic sclerosis. The company is also studying administration without conventional chemotherapy preconditioning in selected cohorts. 29

Mivocabtagene autoleucel, or miv-cel, is a fully human CD19 CAR T product incorporating CD28 costimulation. Kyverna Therapeutics is investigating the asset in neurological autoimmune diseases, including stiff person syndrome, generalized myasthenia gravis, and progressive multiple sclerosis. On October 21, 2026, the company reported one year results from its KYSA-8 registrational study in stiff person syndrome. The rolling biologics license application remained in progress, with completion targeted for the fourth quarter of 2026. These data are sponsor reported and remain subject to regulatory review. 3031

The evidentiary framework for autoimmune indications differs from that used in refractory hematologic cancers. Sponsors must characterize the durability of disease control, changes in background immunosuppressive treatment, organ specific outcomes, immune reconstitution, and late adverse events. The selection of clinically meaningful endpoints and appropriate follow up periods will be particularly consequential where existing therapies provide established alternatives. 12930

Solid Tumors: New Targets and an International Approval

Extending CAR T treatment into solid tumors introduces additional challenges involving antigen selection, penetration into tumor tissue, heterogeneous antigen expression, and inhibitory signals within the tumor microenvironment. The clinical strategy must therefore account for both recognition of malignant cells and the ability of the engineered T cells to retain function in the tumor environment. 3233

A notable regulatory development occurred in China in 2026 with approval of satricabtagene autoleucel, also known as satri-cel, developed by CARsgen Therapeutics. The product targets claudin 18.2 (CLDN18.2) and was approved for selected patients with advanced gastric or gastroesophageal junction adenocarcinoma that is CLDN18.2 positive and HER2 negative following at least two previous treatment lines. The approval represents the first reported regulatory approval of a CAR T cell therapy for a solid tumor. Satri-cel has not received FDA approval in the United States. 33

CLDN18.2 presents a biologically relevant target because it is associated with gastric epithelial tight junction structures and can become accessible to therapeutic recognition in certain malignant tissues. The Chinese approval establishes regulatory precedent within its jurisdiction, while clinical development for other regions must address the applicable local evidentiary, manufacturing, and regulatory requirements. 331

A separate investigational approach targets glypican-3 (GPC3) in hepatocellular carcinoma. C-CAR031 combines GPC3 recognition with an engineered dominant negative transforming growth factor beta receptor II intended to counter inhibitory signaling within the tumor microenvironment. A Phase 1 study published in Nature in July 2026 reported treatment of 36 patients, an objective response rate of 44.4%, and a median response duration of 4.4 months. The findings provide early human evidence of antitumor activity, while the modest response duration and observed resistance mechanisms indicate the continuing need to evaluate durability. 32

In Vivo CAR T: Engineering Cells Within the Patient

In vivo CAR T approaches seek to generate CAR expressing immune cells directly within the recipient through delivery of genetic material. This approach could reduce reliance on the collection, modification, expansion, and shipment of an individually manufactured cellular product. Its clinical feasibility depends on delivery efficiency, cellular specificity, control of transgene expression, and safety. These requirements differ substantially from those of established autologous manufacturing platforms. 2734

Umoja Biopharma has developed investigational in vivo CAR T programs using its VivoVec delivery platform. In July 2026, the company announced FDA clearance of an investigational new drug application for UB-VV400, a CD22 directed candidate intended for selected relapsed or refractory B cell malignancies. The company had previously received authorization to study UB-VV111, a CD19 directed in situ CAR T candidate. These programs illustrate an attempt to shift CAR T production from a manufacturing facility into the patient. 3435

The regulatory challenges include demonstrating selective delivery to intended cells, understanding the distribution and persistence of the genetic construct, establishing adequate expression and activity of the resulting CAR, and evaluating unintended cellular modification. The relevance of integration related safety risks will depend on the vector and delivery technology used. Conventional product release specifications may also require adaptation because cellular engineering occurs after administration. 127

Manufacturing and Patient Access in the United States

The clinical effectiveness of an autologous CAR T product depends in part on whether an eligible patient can receive the manufactured treatment in an appropriate timeframe. The conventional process includes leukapheresis, cell processing, genetic modification, expansion, release testing, shipping, and infusion. A 2024 clinical review of multiple myeloma treatment described manufacturing and quality control periods commonly requiring several weeks, during which patients may require bridging treatment. Delays can be clinically consequential when disease progression is rapid. 2736

Manufacturing timelines should be distinguished from the total interval between treatment selection and infusion. The latter also incorporates referral, patient evaluation, scheduling, collection availability, insurance authorization, and clinical management. Published experience with Carvykti illustrates this distinction: in the CARTITUDE-4 study, the manufacturer reported a median interval of 79 days from first apheresis to infusion among patients who received the investigational study treatment, a measure encompassing more than product manufacturing alone. 436

Payment arrangements and treatment delivery infrastructure introduce separate constraints. The Centers for Medicare and Medicaid Services (CMS) established national coverage for qualifying CAR T treatment of cancer in 2019. Following the June 2025 FDA REMS elimination, Medicare claims requirements were updated to remove the associated facility certification conditions and KX modifier requirements for relevant dates of service. The broader cost of CAR T care includes the product, collection and administration procedures, supportive treatment, management of adverse events, and follow up. 373819

Manufacturing innovation can address some of these limitations through more rapid processing, automation, changes to cellular expansion, and modified treatment logistics. Each change also creates regulatory considerations related to product comparability and the relationship between measurable quality attributes and clinical performance. Sponsors must therefore evaluate manufacturing efficiency alongside the consistency of the resulting cellular product. 127

International Regulatory and Commercial Challenges

Regulatory approval does not guarantee patient access across international markets. A 2026 study published in HemaSphere evaluated commercial availability of CAR T treatments across 30 European countries covered by European regulatory approval and the United Kingdom. Using an August 2024 reference period, the investigators found that 26% of the 31 countries had no commercially available approved CAR T products. Only 16% had commercial access to at least one product for multiple myeloma. These figures describe the study's historical access assessment rather than a verified October 2026 market census. 39

Among European countries with at least one reimbursed CAR T indication, the study reported a median interval of 16.5 months from regulatory approval to reimbursement or early access. Access was considerably faster in certain countries, including Germany and France, while substantially longer delays were observed elsewhere. The median number of qualified treatment centers was approximately five per 10 million population among countries with reimbursed products. Costs, treatment center resources, and reimbursement processes were identified as major barriers. 39

India provides an example of domestic CAR T development intended to address affordability and access. NexCAR19, a locally developed CD19 directed CAR T product, received regulatory authorization in India in 2023 and was publicly launched in April 2024. The US National Cancer Institute described an anticipated treatment price of approximately $50,000, compared with an approximate $400,000 US infusion cost cited at that time. These figures represent historical estimates reported in 2024 rather than standardized or current transaction prices. NexCAR19 has not received FDA approval. 40

China's approval of satricabtagene autoleucel in 2026 also demonstrates the international progression of CAR T technology into new tumor categories. However, authorization in one jurisdiction does not establish market access or approval in another. Regional development programs must account for the accepted clinical evidence, manufacturing arrangements, applicable regulatory standards, and reimbursement requirements within each market. 33139

Regulatory Considerations for the Next Generation

FDA's January 2024 final guidance, Considerations for the Development of Chimeric Antigen Receptor T Cell Products, provides recommendations concerning chemistry, manufacturing, and controls (CMC), nonclinical development, clinical study design, and analytical comparability. The guidance addresses both autologous and allogeneic platforms and recognizes the importance of product specific development decisions. The combination of cellular variability, genetic modification, and biological activity requires an integrated approach to product characterization. 1

For CMC development, sponsors need appropriately justified identity, purity, potency, and other quality measures that reflect the intended product. Relevant attributes may include the proportion of viable CAR expressing cells, cell phenotype, transduction or editing characteristics, functional activity, and process related impurities. Changes to vector systems, cell enrichment methods, manufacturing duration, or production sites may necessitate analytical comparability assessments and additional supporting evidence. 1

Clinical development strategies must address the intended disease setting. In refractory malignancies, response rate, response duration, progression free survival, and other measures may support development depending on the indication and study design. In earlier treatment settings, randomized comparative studies may be more appropriate to establish clinical benefit. Autoimmune programs must identify disease relevant endpoints and meaningful durability measures, while solid tumor programs face additional challenges involving heterogeneous target expression, resistance, and conventional oncology outcomes. 1252932

For allogeneic and in vivo platforms, additional evaluation may be necessary to understand immune compatibility, genetic editing, tissue distribution, persistence, and unintended cellular effects. The selection of preclinical models and clinical monitoring strategies should follow the characteristics of the particular construct and manufacturing approach. FDA's guidance encourages early regulatory interaction when development questions are specific to a new platform or manufacturing strategy. 1

Long term safety remains a major component of the regulatory strategy. Reports of secondary T cell malignancies and additional product specific toxicities demonstrate the importance of sustained follow up, adverse event reporting, and postmarketing evaluation. Sponsors entering new therapeutic areas must also consider whether the acceptable balance of treatment risk and expected benefit differs from that in patients with advanced hematologic malignancies. 2119221

Conclusion

The development of CAR T therapies demonstrates how engineered cellular products can establish a new therapeutic category and subsequently expand through additional indications, improved constructs, and refinements to clinical administration. The seven FDA approved products provide a substantial clinical and regulatory foundation, with differences in target selection, signaling, cell composition, and manufacturing contributing to their distinct product profiles.

The next phase of development encompasses several technological directions. Alternative binding domains and dual antigen recognition seek to improve tumor targeting. Donor derived and in vivo manufacturing approaches seek to address production constraints. Autoimmune applications extend the therapeutic rationale beyond oncology, while emerging solid tumor programs introduce new considerations involving target expression and tumor biology.

Regulatory success will depend on demonstrating clinically meaningful and durable effects, acceptable safety, reproducible manufacturing, and an evidence package appropriate to the intended patient population. International experience also indicates that reimbursement, institutional capacity, and treatment logistics can determine the practical availability of these therapies after authorization. These considerations will shape which CAR T technologies progress from investigational platforms to established treatment options.